Manufacturers report positive results for olaparib with durvalumab in Stage II/III High-Risk, HER2-Negative Breast Cancer in I-SPY2 TRIAL

In this phase II study, patients on durvalumab with olaparib and paclitaxel had a greater pathologic complete response (complete eradication of cancer from breast and axillary lymph nodes at the time of surgery) than those given chemotherapy alone (37% vs 20%).


Biospace Inc.